Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BioNTech SE    BNTX

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Pfizer, BioNTech's Covid-19 Vaccine Candidates Get Fast-Track Designation

share with twitter share with LinkedIn share with facebook
07/13/2020 | 07:28am EDT

By Dave Sebastian

 

Pfizer Inc. and BioNTech SE said two of their four Covid-19 investigational vaccine candidates got fast-track designation from the U.S. Food and Drug Administration that will expedite review.

The companies said the candidates, BNT162b1 and BNT 162b2, are the most advanced among the BNT162 program that is in early clinical studies in the U.S. and Germany.

In premarket trading Monday, Pfizer shares rose 1.5% to $34.34, and BioNTech's ADRs were up 5.1% at $73.99.

Researchers earlier this month said Pfizer and BioNTech's vaccine candidate showed promising signs of working in an early-stage study. Healthy adult volunteers given the vaccine candidate had higher levels of antibodies four weeks after being vaccinated and seven days after getting a second dose, compared with the antibody levels in recovered Covid-19 patients who didn't get the shots, the researchers reported.

The companies said they expect a later-stage study as soon as later this month and anticipate enrolling up to 30,000 participants. If the studies are successful and the vaccine gets regulatory approval, Pfizer and BioNTech said they expect to make up to 100 million doses by the end of the year and more than 1.2 billion doses by the end of 2021.

The companies expect early data from the German study of BNT162b1 to be released this month.

About 13 million people worldwide have contracted Covid-19, and about 4.4% of those people have died, according to data collected by Johns Hopkins University.

 

Write to Dave Sebastian at dave.sebastian@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -3.32% 68.64 Delayed Quote.102.60%
PFIZER LIMITED -1.06% 4486.3 End-of-day quote.6.21%
PFIZER, INC. -0.29% 38.06 Delayed Quote.-2.86%
share with twitter share with LinkedIn share with facebook
Toute l'actualité sur BIONTECH SE
08/14McKesson Tapped to Distribute Coronavirus Vaccines in U.S.
DJ
08/14CUREVAC IN TALKS WITH PHARMA COMPANI : Sueddeutsche
RE
08/14Vaccine makers including Moderna must hit U.S. timing goals for full payments
RE
08/14Vaccine makers including Moderna must hit U.S. timing goals for full payments
RE
08/14Novavax, J&J Ink Covid-19 Vaccine Deals With U.K. -- Update
DJ
08/13PFIZER : UC Davis Health to enroll participants for major COVID-19 vaccine clini..
AQ
08/12BIONTECH : Pfizer and BioNTech Announce Publication of Peer-Reviewed Data from O..
PU
08/11U.S. inks $1.5 billion deal with Moderna for 100 million doses of COVID-19 va..
RE
08/11BIONTECH : Second Quarter 2020 Corporate update and financial results Presentati..
PU
08/11BioNTech Announces Second Quarter 2020 Financial Results and Corporate Progre..
GL
More news
Financials
Sales 2020 472 M 559 M 559 M
Net income 2020 -57,2 M -67,7 M -67,7 M
Net cash 2020 1 287 M 1 524 M 1 524 M
P/E ratio 2020 -181x
Yield 2020 -
Capitalization 13 807 M 16 348 M 16 347 M
EV / Sales 2020 26,5x
EV / Sales 2021 5,13x
Nbr of Employees 1 400
Free-Float 95,0%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 66,39 €
Last Close Price 57,97 €
Spread / Highest target 46,2%
Spread / Average Target 14,5%
Spread / Lowest Target -17,9%
EPS Revisions
Managers
NameTitle
Ugur Sahin Chief Executive Officer
Helmut Jeggle Chairman-Supervisory Board
Sierk Pötting Chief Operating & Financial Officer
Özlem Türeci Chief Medical Officer
Christoph Huber Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BIONTECH SE102.60%16 348
GILEAD SCIENCES, INC.5.42%85 880
VERTEX PHARMACEUTICALS22.08%69 620
REGENERON PHARMACEUTICALS63.14%64 461
WUXI APPTEC CO., LTD.63.95%36 608
GENMAB A/S55.72%23 949